We found that RIPC offers no vascular protection relative to pulmonary artery pressure or peripheral endothelial function during acute, normobaric hypoxia and at high altitude in young, healthy adults. However, peripheral chemosensitivity was heightened 24 h after RIPC at high altitude. 
Introduction
Remote ischemic preconditioning (RIPC) is a non-invasive procedure that has substantial effects on protecting various organs in the body against ischaemia-related injuries. In humans and animal models alike, cyclic 5-10 min periods of occlusion and reperfusion of blood flow through a limb, with total treatment times ranging from 40 to 60 min, produce significant protection against ischaemia in the heart (Murry et al. 1986) , lungs (Kinoshita, 2015) , kidneys (Wever et al. 2011) , liver (Yan et al. 2015 ) and brain (Koch et al. 2011) . The exact mechanisms responsible for these effects remain unclear, but are likely to be a result of activation of various anti-inflammatory and antioxidative pathways (for review, see Koch et al. 2014) .
Recent findings suggest that RIPC might also play a role in protection from hypoxic and altitude-related injuries (Berger et al. 2015b) . For example, in athletes, one session of four bouts of 5 min RIPC treatment in the lower limb attenuates the increase in pulmonary artery systolic pressure (PASP) normally seen after 90 min of normobaric hypoxia (Foster et al. 2011) , and 5 days of consecutive treatment has shown similar pulmonary vascular protective effects when conducted before travel to high altitude (Foster et al. 2014) . Together, these findings suggest that preconditioning might offer a degree of protection against the onset of high-altitude pulmonary oedema. In addition, RIPC has also been linked to reduced oxidative stress and lower symptoms of acute mountain sickness after acute exposure to normobaric hypoxia (Berger et al. 2015a) ; however, these findings were observed only transiently (0-12 h). After a brief period of no observable protection, a second delayed window of protection appears after ß18-20 h and lasts for 1-2 days (Pérez-Pinzón, 2004; Koch et al. 2014) . Although clinical outcomes as a result of RIPC seem promising (Thielmann et al. 2013) , only a very limited number of studies have investigated RIPC and potential further protection against hypoxia (Foster et al. 2011 (Foster et al. , 2014 Berger et al. 2015a) .
High altitude represents an experimental model that allows for the study of hypoxic adaptation in healthy humans. In addition to marked changes in PASP and cerebral blood flow Willie et al. 2014) , ascent to high altitude is typically associated with a decline in vascular function, as demonstrated by impaired endothelium-dependent flow-mediated dilatation (FMD; Lewis et al. 2014; Bakker et al. 2015) and endothelium-independent dilatation . Such impairment in vascular function might further compromise the ability of the body to tolerate the various stresses associated with hypoxia. Increased sympathetic nerve activity and disturbed blood flow may contribute to the hypoxia-associated reduction in FMD Tremblay et al. 2017) . Additionally, the impairment might be attributed to an increase in oxidative stress, which might interfere with the intracellular signalling processes required for smooth muscle relaxation (Münzel et al. 2004) . Remote ischemic preconditioning reduces oxidative stress after ischemic injuries (Chen et al. 2015) , and these same activated pathways might also attenuate the decline in vascular function at high altitude. Furthermore, RIPC has been demonstrated to preserve FMD immediately after strenuous exercise (Bailey et al. 2012) , a period that is normally associated with elevations in sympathetic nerve activity and a temporary impairment in vascular function Tymko et al. 2016b) .
Therefore, the primary aim of this study was to explore the potential protective benefits a single session of RIPC (four bouts of 5 min) on integrative vascular function during both acute and chronic exposure to hypoxia. The previously observed reduction in PASP and improved haemoglobin saturation at altitude in response to RIPC (Foster et al. 2014 ) could potentially be explained by a larger hypoxic ventilatory response (HVR), although this possibility has not yet been investigated. Therefore, a secondary objective of this study was to examine whether RIPC evokes any changes in peripheral chemosensitivity to hypoxia. Finally, based on reports that RIPC offers two distinct protective windows (Koch et al. 2014) , from 0 to 12 h and again from 18 to 72 h, measurements were repeated immediately (1 h), 24 and 48 h after the initial RIPC treatment. We hypothesized that RIPC of the lower limbs would reduce the increase in pulmonary artery pressure normally observed in hypoxia (Swenson, 2013) , as well as attenuate the hypoxic impairment in FMD . We also reasoned that the RIPC intervention would increase the HVR, thereby explaining the previously reported elevations in peripheral oxygen saturation (S pO 2 ; Foster et al. 2014) . Given that >80 million of people live above 2500 m and many more travel to altitude per year, with 10-85% of these getting some form of altitude illness (Hackett et al. 1976; Maggiorini et al. 1990) , determining the impact of RIPC might provide a simple and inexpensive strategy to alleviate high-altitude-related illnesses. 24.1 ± 3.6 24.7 ± 3.7 23.9 ± 3.4 27.5 ± 2.9 Weight (kg)
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Abbreviation: RIPC, remote ischemic preconditioning. There were no differences in subject demographics (age, height and weight) between treatment conditions or between acute and chronic hypoxia branches of the study (P > 0.05).
Methods
This experiment was conducted in two separate parts, with one protocol taking place near sea level (SL; Kelowna, BC, Canada; 344 m) and the second protocol starting after 8-10 days at high altitude (HA; Barcroft Station, White Mountain, CA, USA; 3800 m). This study was a part of a series of experiments that took place over the course of a 2 week research expedition to Barcroft Station, starting with rapid ascent to high altitude (3800 m, <6 h drive) on day 1. There was no overlap between participation in this study and participation in other investigations relative to carry-over effects of drugs and/or exercise, and the questions addressed in this paper are dealt with exclusively within this study alone. During the entirety of their stay at Barcroft Station, participants had access to regular meals and fluids ad libitum. All participants abstained from vigorous exercise, caffeine and alcohol for 12 h before testing and were asked to consume a light snack 2 h before coming to the laboratory.
Participants
All participants were free of overt cardiovascular, respiratory and cerebrovascular disease, were non-diabetic and not taking any prescription medications (other than oral contraceptives, n = 2) at the time of their participation, as determined by a screening questionnaire. Each subject provided written informed consent before arrival at the laboratory for familiarization. Participants were different for the SL and HA components of the study, with select characteristics described below and in 
Experimental design
Part 1: sea level (acute hypoxia). Participants came into the laboratory on three consecutive days, where the protocol was performed on the first day (baseline; BL) and then repeated again at the following three time points: 1 (day 1), 24 (day 2) and 48 h (day 3). The testing protocol is depicted in Fig. 1 . Immediately after BL, subjects were randomly allocated into either dual-thigh RIPC or a sham treatment, both of which are described below. For each session (BL, 1, 24 and 48 h), subjects lay supine while being instrumented for the tests (described further in the subsection on 'Experimental measurements'). After 20 min of supine rest, normoxic echocardiographic images were obtained. Next, a baseline FMD test of the brachial artery was performed, followed by 5 min of rest, where baseline minute ventilation (V E ), peripheral oxygen saturation expressed as a percentage (S pO 2 %), blood pressure (BP) and middle cerebral artery blood velocity (MCAv) were collected. Subjects breathed on an end-tidal air forcing system (described below), where the end-tidal partial pressures of O 2 and CO 2 (P ET,O 2 and P ET,CO 2 , respectively) were clamped to match previously measured room air values. Once a steady state was achieved, the ultrasonographer began scanning the internal carotid artery (ICA) and obtained at least 1 min of satisfactory recordings before the isocapnic hypoxia stage. The sonographer held the image of the ICA in place as P ET,O 2 was subsequently and rapidly dropped to 50 mmHg, while P ET,CO 2 was maintained at room-air values. From the establishment of steady state, ICA images were then obtained continuously over the first 10 min of hypoxia. Starting at minute 15, a second brachial artery FMD was performed, followed by echocardiographic image acquisition (for PASP) at minute 30. Therefore, room air and hypoxia measures were collected in every visit. The level of hypoxia (P ET,O 2 = 50 mmHg) was selected in order to provide an approximated, comparable hypoxic stimulus to that experienced during the subsequent HA component of the study at Barcroft Station (Severinghaus et al. 1966) .
Part 2: high altitude (chronic hypoxia). A similar time profile was used to the sea-level study. Subjects were tested on three consecutive days, between the eighth and 12th day of continuous residence at the Barcroft Station (3800 m), where the protocol was performed on the first day (BL) and repeated at the following three time points: 1 (day 1), 24 (day 2) and 48 h (day 3). The experimental protocol is depicted in Fig. 2 . Immediately after BL, subjects were randomly allocated to either dual-thigh RIPC or a sham treatment which acted as a time-based control. Consequent to our limited participant pool at HA, eight participants were selected to receive RIPC in order to identify more clearly any physiological changes after treatment, and the remaining four served as a time control subset. Cardiorespiratory changes throughout acclimatization have been well documented, and after the first week, day-to-day changes in heart rate (HR),V E and S pO 2 are minimal (Swenson & Bärtsch, 2014) .
While resting in the supine position, subjects were instrumented for testing. After 20 min of rest, echocardiographic images (for PASP) were acquired, followed by an FMD test of the brachial artery. Baseline ventilatory measurements were then taken, followed by end-tidal forcing, clamping P ET,O 2 and P ET,CO 2 to BL values. The ICA velocity and diameter were measured for at least 1 min, followed by a subsequent isocapnic reduction in P ET,O 2 to 45 mmHg. This level of hypoxia was selected in order to provide a significant hypoxic stimulus beyond what was already being experienced by the participants at Barcroft Station. Once a steady state was achieved, ICA measures were taken for 10 min, along with measures ofV E , S pO 2 %, BP and MCAv.
Remote ischemic preconditioning
Participants were seated in a chair with blood pressure cuffs placed around both legs at mid-thigh level. At sea level, an automated rapid inflation system was used to inflate the cuffs quickly to 225 mmHg, whereas at high altitude a manual hand pump was used to increase the cuff pressure. The cuffs remained inflated for 5 min, followed by a 5 min period of deflation, allowing for reperfusion of blood flow to the limb. This process was repeated four times, for a total treatment time of 40 min (Foster et al. 2014) . In the time control and sham conditions, the cuffs were inflated to only <20 mmHg. We chose this method of dual-thigh occlusion in order to simulate an easily reproducible treatment that could be applied at short notice in remote locations, with minimal time and equipment. In practice, it could be used in situations where rapid ascent to altitude is required with short notice or as a treatment to mitigate risk in those already in a hypoxic setting.
Experimental measurements
Cardiorespiratory. In both studies, at sea level and high altitude, cardiorespiratory variables were sampled continuously throughout the protocol at 1 kHz via an analog-to-digital converter (Powerlab, 16/30; ADInstruments, Colorado Springs, CO, USA). A threelead ECG (ADI bioamp ML132, ADInstruments, Colorado, USA) was used to measure HR, and beat-tobeat blood pressure was recorded by finger photoplethysmography (Finometer PRO; Finapres Medical Systems, Amsterdam, The Netherlands). The Finometerreconstructed brachial waveform was used for calculation of mean arterial pressure (MAP) after back calibrating to the average of three automated brachial blood pressure cuff measurements made at rest (Tango+; Suntech, Morrisville, NC, USA). Respiratory flow anḋ V E were measured by a pneumotachograph (HR800L; HansRudolph, Shawnee, KS, USA) connected in series to a bacteriological filter, and a calibrated gas analyser (ML206; ADInstruments) was used to record the partial pressure of both P ET,CO 2 and P ET,O 2 , sampled at the level of the mouth. Arterial O 2 saturation was measured continually using pulse oximetry (ADInstruments). All measures, unless otherwise stated, are reported as averages over 1 min bins. In the acute hypoxia protocol, hypoxic cardiorespiratory measurements are taken between minutes 25 and 30 of isocapnic hypoxia. In the chronic hypoxia protocol, hypoxic measurements are taken between minutes 9 and 10 of isocapnic hypoxia. These time frames were chosen as the most suitable representations of the steady state for each test.
End-tidal forcing. A dynamic end-tidal forcing system was used to control P ET,CO 2 and P ET,O 2 during the normoxic and isocapnic hypoxic periods of the protocols. This system has previously been described in detail (Tymko et al. 2015 (Tymko et al. , 2016a and is able to control end-tidal gases effectively independent of ventilation at low and high altitudes. The P ET,CO 2 was kept constant at resting room air values throughout the two protocols, whereas P ET,O 2 was rapidly lowered during the transition from room air to hypoxia until a steady state was achieved; this was determined as at least three consecutive breaths within 1 mmHg of the desired target.
Peripheral chemosensitivity. After the onset of hypoxia, ventilatory and end-tidal data were averaged into 15 s bins. The HVR was calculated using the peak 15 s bin of ventilation following the transition from normoxia to isocapnic hypoxia on the end-tidal forcing system (described in the previous subsection). This peak 15 s bin was compared with a 30 s bin of data collected immediately before the hypoxic drop, and the HVR was thus calculated using the following formula: HVR = V E / S cO 2 %, with S cO 2 (calculated oxygen saturation) calculated from the end-tidal O 2 trace using the equation described by Severinghaus (1979) . We used this equation to calculate saturation over pulse oximetry in order to reflect more accurately the timing of changes in blood oxygenation.
Flow-mediated dilatation. Reactive hyperaemia flowmediated dilatation was performed according to internationally recognized guidelines (Thijssen et al. 2011) . Participants were lying supine with their left arm extended in a fixed position ß80 deg perpendicular from their body. All measurements were taken after at least 20 min of supine rest in a quiet, dark room. Brachial artery image acquisition was obtained using a 10 MHz multifrequency linear array probe attached to a high-resolution ultrasound machine (15L4, Terason T3200; Teratech, Burlington, MA, USA). All images were acquired by the same experienced ultrasonographer (J.C.T.), who has a between-day coefficient of variation in FMD of 8.3 ± 2.1% (n = 10; Tremblay JC, unpublished data). After optimal image acquisition and 1 min of baseline recordings, the forearm was occluded by inflating the cuff to 220-250 mmHg for 5 min. Recordings of diameter and velocity continued 30 s before cuff deflation and continuously for 3 min thereafter. Video recordings were anonymized and stored for later offline analysis using specialized edge-detection software (Woodman et al. 2001; Thijssen et al. 2011) . Flow-mediated dilatation was calculated as the peak increase in diameter after cuff deflation. The FMD stimulus was calculated as the shear rate area under the curve (SRAUC) from the onset of reactive hyperaemia to FMD (Pyke & Tschakovsky, 2007) .
Measurement of extra-and intracranial blood flow. A 10 MHz multifrequency linear array duplex ultrasound machine (Terason T3200; Teratech) was used to measure blood velocity and diameter of the ICA. These recordings were acquired using simultaneous B-mode imaging (diameter) and pulse-wave mode (velocity). In order to eliminate recordings of turbulent and retrograde flow, measurements were taken at least 1.5 cm distal to the common carotid bifurcation. To avoid any artificial changes in arterial wall brightness/thickness, there was no alteration in B-mode gain upon acquisition of the first ultrasound image. Data were anonymized and later analysed offline using the same edge-detection software as described in the previous subsection, and values are reported as an average over a minimum of 12 consecutive cardiac cycles. Flow reactivity was calculated using a 30 s bin encompassing the peak response to hypoxia.
Blood velocity through the left middle vertebral artery (MCAv) was recorded using a 2 MHz transcranial Doppler ultrasound machine (Spencer Technologies, Seattle, WA, USA). A specialized headband (model M600 bilateral head frame; Spencer Technologies) was used to secure the probe in place. Insonation was achieved through the trans-temporal window using previously described location and standardization techniques (Willie et al. 2011) , and data are reported as the average across selected 30 s bins during each stage.
Echocardiography. All echocardiographic images were obtained by the same experienced sonographer (MS) on a commercially available ultrasound machine [Vivid Q (SL) or E9 (HA); GE, Fairfield, CT, USA). M5-S 1.5-4.6 MHz and 4V 1.5-40 MHz transducers were used to collect echocardiographic images, which were saved for offline analysis (Echopac v.113; GE). Subjects lay in the supine left lateral decubitus position. The modified Bernoulli equation was used to calculate pulmonary artery systolic pressure, where PASP = 4V 2 + 5 mmHg, where V equals the peak tricuspid regurgitation velocity and 5 mmHg was added for right atrial pressure where the inferior vena cava collapsed under inspiration (Rudski et al. 2010) . Measures of PASP are reported using the average of at least three cardiac cycles.
Statistical analysis
Based upon previous studies investigating FMD and PASP during hypoxia, sample sizes of 9-12 (Foster et al. 2014; Jones et al. 2014b; Lewis et al. 2014) were able to show significant changes. We therefore attempted to have >10 participants in each group; however, the time allocated and subject availability for this study allowed us to have only eight participants in each group at SL, and a small subset of four time control participants in the HA trial. For example, during isocapnic hypoxia at SL, if we were to assume a PASP of 30 mmHg and wished to detect a 10% reduction following RIPC, with a standard deviation of the differences of 2.5 mmHg, a power of 0.8 and α of 0.05, we would need 10 participants. Results from this study must therefore be treated as preliminary rather than confirmatory, and further studies using larger sample sizes are needed.
In part 1 (acute hypoxia), a two-way repeated-measures ANOVA was used for the cardiovascular measures in each treatment group (factors: time and O 2 ). In addition, a two-way repeated-measures ANOVA (factors: time and treatment) was used to identify differences in the HVR and ICA reactivity, as well as the change from normoxia to hypoxia for FMD and PASP. In part 2 (chronic hypoxia), independent one-way ANOVAs were used on both the RIPC group and the time control group (factor: time). Upon detection of significant main effects, pairwise comparisons were made using Dunnett's t tests. Although it has recently become convention to scale FMD changes allometrically (Atkinson & Batterham, 2013) and scale for SRAUC as a covariate (Atkinson & Batterham, 2015) , baseline diameter and SRAUC did not differ between groups in the present study and were therefore not corrected for. Furthermore, the normality of all the main outcome variables (FMD, PASP, internal carotid artery flow [qICA] , V E and HVR) was confirmed using a Shapiro-Wilk test. All data were analysed using SPSS (version 24; IBM, Surrey, UK). Results are reported as means ± SD unless otherwise indicated. Statistical significance was defined as P < 0.05.
Results

Part 1: sea level (acute hypoxia)
Cardiovascular responses. Table 2 presents cardiovascular and respiratory variables during baseline and during isocapnic hypoxia (P ET,O 2 clamped to 50 mmHg). There were no significant differences in the magnitudes of responses to hypoxia in HR (RIPC, P = 0.91; sham, P = 0.91), MAP (RIPC, P = 0.51; sham, P = 0.37) or S pO 2 (RIPC, P = 0.84; sham, P = 0.98) at any time point in either the RIPC or the sham conditions. Pulmonary artery pressures. Pulmonary pressures during normoxia and hypoxia are presented in Table 2 . One subject was excluded from each group because of a lack of suitable echocardiographic images for measuring tricuspid regurgitation; thus, statistical analysis was based on seven participants in each group. Although hypoxia consistently increased PASP during each trial (P < 0.01 for both RIPC and sham), the magnitude of this increase did not differ between trials ( Fig. 3 ; P = 0.60).
Flow-mediated dilatation. Brachial artery FMD (as a percentage dilatation) responses during normoxia and hypoxia are shown in Table 2 . There were no differences in baseline diameter (RIPC, P = 0.67; sham, P = 0.83) or SRAUC (RIPC, P = 0.40; sham, P = 0.99) and, subsequently, no changes in FMD response at any time in either of the conditions. The FMD (as a percentage dilatation) is presented in Table 2 .
Internal carotid artery flow and intracranial velocity.
Isocapnic hypoxia resulted in a comparable increase in C 2017 The Authors. Experimental Physiology C 2017 The Physiological Society Remote ischemic preconditioning and vascular function blood flow through the ICA (P < 0.01 for both RIPC and sham) and blood velocity in the MCA (P < 0.01 for both RIPC and sham) in both conditions, although neither response differed between RIPC and sham at any point throughout the protocol (Table 2 for MCA and Fig. 3 for ICA).
Ventilation. Ventilation was elevated during hypoxia (P < 0.01 for both RIPC and sham); however, there were no differences in ventilation across any of the testing times (RIPC, P = 0.58; sham, P = 0.89; see Table 2 ). The HVR (Fig. 3) was also unaffected by either RIPC or sham treatment (P = 0.45). Pulmonary artery pressures. Reliable echocardiographic images were obtained from seven participants from the RIPC group and four from the time control group. The PASP (Fig. 4) was unchanged from baseline after treatment in either group (RIPC, P = 0.64 versus time control, P = 0.88).
Flow-mediated dilatation. Flow-mediated dilatation of the brachial artery did not differ from baseline at any point after RIPC (P = 0.89) or after time control (P = 0.41; Fig. 4 ). There were no significant differences in response from normoxia to hypoxia (i.e. normoxia % − hypoxia %). C, peak flow reactivity of the internal carotid artery (ICA) upon the transition from normoxia to hypoxia. D, the hypoxic ventilatory response (HVR). Filled bars represent means for RIPC; grey bars represent means for Sham. End-tidal partial pressure of O 2 was clamped at 50 mmHg in isocapnic conditions in the hypoxia phase. Testing was to model acute hypoxia, performed at low altitude (344 m). Individual data points are shown, and bars represent group means. A 2 × 4 ANOVA (factors: time and treatment) was used to identify significant differences; P > 0.05 for all interactions. S pO 2 , peripheral oxygen saturation expressed as a percentage; S cO 2 , calculated oxygen saturation expressed as a percentage. Remote ischemic preconditioning and vascular function 
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baseline diameter or SRAUC in either group (P > 0.05 for all).
Internal carotid artery flow and intracranial velocity.
Blood flow through the ICA and velocity in the MCA both increased upon the transition from room air to isocapnic hypoxia (P < 0.05 for both; see Table 3 ), although the magnitude of this increase did not change after either treatment (RIPC, P = 0.51 and time control, P = 0.39).
Ventilation. Resting room air ventilation was unaffected by time in either treatment group; however, the HVR was higher than at baseline after 24 h treatment with RIPC. For example, HVR at baseline was 2.05 ± 1.4 l min (% arterial O 2 saturation) −1 , compared with 1 [2.44 ± 1.3 l min (% arterial O 2 saturation) −1 ; P = 0.80], 24 [3.21 ± 1.2 l min (% arterial O 2 saturation) −1 ; P = 0.04] and 48 h [2.79 ± 1.5 l min (% arterial O 2 saturation) −1 ; P = 0.21] after RIPC (Fig. 4) . This increase was driven by an elevation inV E peak (P = 0.02) andV E average (P = 0.03) during hypoxia, 24 h after RIPC treatment (Table 3) .
Discussion
The aim of this study was to explore the potential protective effects of a single session of four bouts of 5 min of RIPC on the peripheral, cerebral and pulmonary vasculature during exposures to acute and chronic hypoxia. By using tightly controlled hypoxic episodes within the laboratory, as well as prolonged high-altitude exposure in the field, we were able to test early and late protective windows of RIPC in acute and chronic hypoxic models. We hypothesized that our method of RIPC would induce prophylactic vascular benefits during exposure to acute hypoxia, as well as therapeutic benefits during chronic hypoxia. Contrary to our hypotheses, we did not observe any discernable benefits in the form of reduced PASP, improved peripheral vascular function (i.e. FMD) or alterations in cerebral perfusion or cerebrovascular reactivity to hypoxia. We do, however, report an increase in the isocapnic HVR in the late protective window (24 h) after RIPC treatment at high altitude (3800 m). Although hypoxic chemosensitivity might increase following RIPC at HA, the absence of any accompanying benefits on resting oxygenation or the vasculature suggests that the utility of a single RIPC session seems unremarkable during acute and chronic hypoxia.
Experimental models of RIPC. Previous research investigating the utility of RIPC has been largely focused on clinical populations, with the goal of improving outcomes after stroke (Dave et al. 2006; Ren et al. 2008) , myocardial infarction (Gho et al. 1996; Costa et al. 2013; Man et al. 2017 ) and a number of ischaemia-related injuries (reviewed by Tapuria et al. 2008) . Remote ischemic preconditioning appears to reduce biomarkers of tissue and neuronal damage after numerous surgical interventions (reviewed by Candilio et al. 2013) ; however, two recent large-scale clinical trials (with concurrent propofol use) have failed to show an improvement in clinical outcomes when using RIPC before coronary artery bypass grafting (Hausenloy et al. 2015; Meybohm et al. 2015) . Despite extensive research into clinical utility, very little research has investigated whether RIPC elicits vascular benefits to those exposed to hypoxia, and if a minimal stimulus is required to elicit any of the potential benefits. For example, RIPC can be structured in a number of different ways, with ischemic episodes ranging from 4 to 10 min, repeated three to six times within a treatment, and the volume of total treatments ranging from 1 or 2 days to weeks or months of consecutive daily treatment (Eisen et al. 2004; Meng et al. 2012) . We sought to pursue a simple, conservative and potentially practical form of treatment, using four consecutive 5 min periods of dual-thigh-cuff occlusion, interspersed with 5 min of reperfusion, for a single 40 min session. This approach was chosen because it is logistically simple and would be easy to perform as a field tool in normal trekking circumstances. We took repeated measurements at three separate points after the treatment to evaluate differences in previously established early (1-16 h) and late (18 h to 2-3 days) protective windows (Koch et al. 2014) . Although the protective effects of RIPC have commonly been attributed to the upregulation of antioxidative and anti-inflammatory pathways, the exact pathways being used seem to vary based on the target organ, and the mechanisms of activation are still unclear. Furthermore, how these pathways translate into physiological changes is relatively unknown.
Remote ischemic preconditioning and peripheral vascular function. In humans, long-term RIPC (daily, for 1 month) has been associated with improvements in resting endothelial function (Kimura et al. 2007) . This is likely to be attributable to RIPC-triggered signalling for the upregulation of the NO system (Gattullo et al. 1999; Kimura et al. 2007; Arroyo-Martínez et al. 2016) as well as the release of vasoactive molecules, such as adenosine and bradykinin (Lim & Hausenloy, 2012) , which may trigger increases in reactivity of the endothelial lining. Furthermore, recent research suggests that RIPC treatment may reduce sympathetic tone (Lambert et al. 2016) , which would be likely to alter reactivity of the peripheral arteries to changes in shear stress. Improvements in resting FMD in healthy subjects have also been reported after seven consecutive days of RIPC treatments (Jones et al. 2014a) , and it has been demonstrated that one session of RIPC offers protection against ischaemia-reperfusion injury-induced (Liu et al. 2015) and exercise-induced (Bailey et al. 2012) impairments in FMD. However, in this latter study, and consistent with our findings, it was reported that resting FMD immediately after one treatment was unchanged. Our findings suggest that baseline and hypoxic FMD responses are unaffected by single-session RIPC treatment, although we also report no significant reduction in FMD upon the acute transition from normoxia to hypoxia. Two probable causes may contribute to this finding; either the duration or level of hypoxia was too small to elicit a reduction in FMD (measured after 15 min in acute hypoxia), or the magnitude of reduction in FMD was too small to identify with our sample size. There is emerging evidence that impairment in FMD is not a uniform response to hypoxia and may depend on severity, duration, concomitant exercise Tymko et al. 2016b; Tremblay et al. 2017) or the presence of cardiovascular risk factors (Frøbert et al. 2008) . In the present study, failure to alter FMD with RIPC could subsequently be explained by the lack of a meaningful vascular impairment in our model of hypoxia.
Remote ischemic preconditioning and pulmonary vascular tone. It has been previously reported that a single session of RIPC before breathing a hypoxic gas mixture for 90 min blunts the increase in PASP (Foster et al. 2011) . Furthermore, after pretreatment with five consecutive days of RIPC before rapid ascent to high altitude (followed by an exercise challenge), the increase in PASP was also mitigated (Foster et al. 2014) . Mechanisms for this attenuation of hypoxic pulmonary vasoconstriction remain speculative and are poorly understood. During the chronic hypoxia (HA) component of our study, the increase in PASP could be at least partly attributed to a degree of pulmonary vascular remodelling, a complex process with proliferative and inflammatory components (Stenmark et al. 2006 ) that might be affected by RIPC; however, the magnitude and time course of remodelling with hypoxia are still unclear. Results from our study suggest that there is no change in the amplitude of the PASP response to hypoxia after RIPC in either acute or chronic hypoxia; however, our measures were taken only 30 min into the acute hypoxic challenge at a point when PASP is still rising . Furthermore, we used a single session versus a 5 day repeated protocol, which might lead to dose-dependent effects. Different, overlapping mechanisms might be responsible for the initial rapid increase and subsequent slow intensification of pulmonary artery pressures (Vejlstrup et al. 1997) in response to hypoxia, and delaying our measurements to 90-120 min might have yielded different results. However, at altitude, where subjects were hypoxic for 8-12 days, RIPC failed to elicit any changes in PASP, indicating that the time of measurement probably does not explain our lack of effect at SL. At HA, all participants exhibited a moderate elevation in PASP that is comparable with other high-altitude studies (Antezana et al. 1998) . Based on reports of reduced measures of NO bioavailability and increased production of endothelin-1 (Sartori et al. 1999; Bailey et al. 2010) , we speculate that RIPC might differentially affect those with exaggerated HPV responses who are susceptible to high-altitude pulmonary oedema, although this hypothesis has yet to be tested.
Remote ischemic preconditioning and peripheral chemosensitivity. A new finding of the present study is that RIPC augments the HVR during chronic hypoxia (Fig. 4) . We did not attempt to investigate any mechanisms underlying changes caused by RIPC, although this finding broadly supports previous observations by Foster et al. (2014) that RIPC improves oxygen saturation upon ascent to high altitude. Sensitivity of the carotid body relies on the balance of numerous systemic factors, many of which vary significantly on a daily basis, leading to a large daily intra-individual variation in the hypoxic ventilatory response. Mechanisms underpinning the observed increase in chemosensitivity are purely speculative, but might involve increased release of neurotransmitters, such as 5-hydroxytryptamine, or a hypoxia-inducible factor-1-aided improvement in oxygen sensing (Nurse, 2010; Prabhakar & Semenza, 2016) .
Methodological considerations.
A large amount of uncertainty still exists over the nature and optimal magnitude of the ischemic stimulus required to elicit the desired protective benefits of RIPC. An emerging pattern seems to suggest that there might be a dose-response relationship, i.e. thigh occlusion is more effective than arm occlusion; dual-thigh treatment is more effective than single-thigh treatment; and more ischemic repeats and more consecutive days of treatment have an additive effect compared with single sessions (Koch et al. 2014) . Inevitably, caution must be exercised, because the goal of ischemic preconditioning is to deliver small, non-lethal bouts of ischaemia to an area, rather than creating a real ischemic injury in the distal tissue. If we had used a longer duration of ischaemia, more repeats, or added consecutive days of treatment, we might have observed different results; however, the aim of the present study was to explore the efficacy of one simple session of RIPC, with the goal of offering a simple prophylactic treatment to those travelling to high altitude on short notice, or a quick therapeutic and practical aid for those who might be experiencing signs of mountain sickness.
With a treatment such as RIPC, it is difficult to deliver a true 'sham' protocol, because it is impossible to blind a subject to the obvious physical sensations associated with cuffs being inflated to 225 mmHg over the thighs. For this reason, naive subjects were verbally informed that the aim of the study was to explore differences between arterial (200 mmHg) and venous (20 mmHg) occlusion during their respective trials.
We also acknowledge that the lack of an equally weighted control group in the HA arm; however, with limited time and a small participant pool afforded to the study, we were able to use only four subjects to act as a time control. The most significant changes in acclimatization status occur within the first few days of arrival at high altitude (Swenson & Bärtsch, 2014) , and we observed no changes in ventilation or any other physiological parameters in our time control group, suggesting that any acclimatization occurring between days 8 and 12 over the course of the study had little effect on our findings.
Given the small sample size and lack of a repeated-measures control, these data must be interpreted judiciously and considered more exploratory than confirmatory. For example, power calculations indicate that a much larger sample size (n > 250) would have been needed to observe significant changes (>1%) in FMD with a power of 0.8. However, this is not feasible in high-altitude research and supports the negligible influence of RIPC on FMD in hypoxia.
Conclusions
Our preliminary results indicate that one session of four bouts of 5 min dual-thigh RIPC treatment seems to have no benefit in terms of pulmonary vascular protection or preservation of peripheral endothelial function during acute and chronic hypoxia. Continued exploration of potential protective benefits that might be derived from using different RIPC treatment strategies may be useful. An improved HVR 24 h after preconditioning during chronic hypoxia suggests that RIPC can influence the hypoxic chemosensitivity of the carotid body. The HVR has been positively related to exercise performance at high altitudes (<6100 m; Schoene et al. 1984) ; however, as resting S pO 2 was unchanged, and an enhanced peripheral chemosensitivity might augment periodic breathing at altitude (reviewed by Ainslie et al. 2013) , whether these changes are of advantage seems unlikely.
